Engineering the future of precision radiotherapeutics
Abdera is combining advanced antibody engineering with radiotherapeutics to attack cancer in bold new ways.
A custom-engineered approach to targeted radiotherapeutics
Abdera’s ROVEr™ platform integrates cutting-edge drug discovery and antibody engineering technologies to advance novel radiopharmaceutical-based cancer medicines with tunable PK properties focused on maximizing therapeutic effect while mitigating systemic toxicities.
Tunable precision cancer therapies
Abdera is building a pipeline of potential best-in-class radiotherapeutics capable of delivering alpha- or beta-emitting radionuclide payloads to a broad range of emerging and clinically validated solid tumor targets. Abdera’s lead program targets DLL3, a protein that is specifically expressed in small cell lung cancer (SCLC) and other solid tumors.
Pioneers in radiotherapeutics
We are led by an exceptional team of scientists and company builders with demonstrated track records in drug development and expertise spanning oncology, radiotherapeutics and biologics.